MDMA-assisted Therapy Market

MDMA-assisted Therapy Market - Global Industry Analysis 2016 - 2020 and Opportunity Assessment 2021 - 2031

MDMA-assisted Therapy Market Segmented By Post-traumatic stress disorder, Anxiety in terminally ill patients, Social anxiety in autistic adults Indication in Hospital pharmacies, Retail pharmacies, Online pharmacies

MDMA-assisted Therapy Market Forecast and CAGR

According to the latest research by Persistence Market Research, the MDMA-assisted therapy market is set to witness positive growth of CAGR 3.4% during 2021-2031. MDMA (3-4 methylenedioxymethamphetamine) is a drug that can be used in posttraumatic stress disorder (PTSD), the anxiety caused due to end-stage diseases like cancer.

PTSD can occur after any traumatic event or can occur with depression and anxiety. The MDMA- assisted therapy market is mainly driven by the increase in the prevalence of PTSD, anxiety, new products in the pipeline and government initiatives for treatment of PTSD. The companies are exploring treatment options for PTSD with the help of derivatives of MDMA and different combinations.

Find Out More about the Report Coverage

What Is Driving Demand for MDMA-assisted Therapy?

MDMA- assisted therapy includes treatment of posttraumatic stress disorder, anxiety related to end-stage diseases like cancer, social anxiety in autistic patients, etc. According to the national centre for PTSD, about 6% of the population will have PTSD at some point in their lives. Also, in the U.S. during a given year about 15 million people suffer from PTSD. This increasing prevalence of PTSD will drive the market in the forecasted period.

The initiatives taken by the government for the awareness of anxiety and post-trauma stress will drive the market. For instance, the U.S. is the helpline centre for veterans who are diagnosed with PTSD or suffer from the same. In addition, the firms are working on clinical trials for using MDMA as a medication to treat PTSD.

Moreover, an increase in the awareness about MDMA-assisted therapy and R & D investment by the companies for developing new products is expected to increase demand for MDMA-assisted therapy during the forecast period.

Customize this Report

Explore Intelligence Tailored to Your Business Goals.

Who Are The Key Manufacturers Of MDMA-assisted Therapy?

Currently, there are no FDA approved MDMA drugs available in the market. However, the companies are involved in clinical trials for the treatment of post-traumatic stress disorder (PTSD), anxiety related to cancer, depression etc. For instance, in 2019, Atai Life Sciences and Bionomics partnered together for exploring the combination treatment regimen.

This combination included EmpathBio’s MDMA derivative, EMP-01, and Bionomics’ lead drug candidate, BNC210.  Apart from this, in June 2021, Awakn Life Sciences Corp. has filed a patent application for its MDMA-derived new chemical entities, AWKN001 and AWKN002 for the treatment of a broad range of addictions.

Market Research Methodology - Perfected through Years of Diligence

A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.

Get actionable insights on Ship Repair And Maintenance Services Market

Regional outlook Of MDMA-assisted Therapy Market

The MDMA –assisted therapy market is mainly dominated by North America with countries like the US and Canada is dominating the MDMA-assisted therapy market. This is due to the presence of major players like Awakn Life Sciences and the government initiatives to spread awareness about post-trauma stress.

Another region that is expected to dominate the market is Europe followed by Asia. This is because PTSD is common in this area. According to a study published in Oxford Medicine, PTSD affects approximately 1% to 3% of the European population every year.

Explore Persistence Market Research’s expertise in promulgation of the business !

Key Segments

By Indication

  • Post-traumatic stress disorder (PTSD)
  • Anxiety in terminally ill patients
  • Social anxiety in autistic adults

By Distribution Channel

  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies

By Region

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East and Africa

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain.

The report provides an in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

MDMA-assisted Therapy Market Report Highlights:

  • Detailed overview of the parent market
  • Changing market dynamics in the industry
  • In-depth market segmentation
  • Historical, current and projected market size in terms of volume and value
  • Recent industry trends and developments
  • Competitive landscape
  • Strategies of key players and products offered
  • Potential and niche segments, geographical regions exhibiting promising growth
  • A neutral perspective on market performance
  • Must-have information for market players to sustain and enhance their market footprints

NOTE - All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of the company.


Polycystic Ovarian Syndrome Drugs Market

Global polycystic ovary syndrome drugs market revenue is estimated to reach US$ 1,154.8 Mn by 2024, expanding at a CAGR of 4.6% during the forecast period 2016–2024.

Compression Socks Market

The global compression socks market is expected to expand at a considerable growth over the next ten years at a CAGR of around 5%, and observe an increase in the value from US$ 630 Mn in 2021 to over US$ 1 Bn by the end of 2031..

Hypercholesterolemia Treatment Market

The global hypercholesterolemia treatment market is anticipated to grow from a valuation of US$ 27 Bn in 2022 to US$ 34 Bn by the end of 2032, progressing at a CAGR of 2.3% through 2032..

Rare Endocrine Disease Treatment Market

Rare Endocrine Disease Treatment Market over the period of forecast, 2017 to 2026. Revenues from treatment of rare endocrine diseases are envisaged to reach approximately US$ 12,000 Mn by 2026-end..

Our Clients

Our Clients